Candidate Pipeline

Boulder BioScience is currently developing two hospital-dispensed, critical care drug candidates for treatment of Acute Ischemic Stroke (AIS) and Traumatic Brain Injury (TBI) including Concussion.

The company’s lead drug candidate, BR9001, provides a first-in-class small molecule for oral administration as a “field formulation” for mild TBI and concussions, and for pre-hospital use in screened AIS patients. BR4044 is an intravenous injection formulation of the API suitable for administration by emergency professionals following TBI and by interventional neuro-radiologists before and during Thrombectomy for AIS.

Candidate
Route of Administration
Indication
Early Preclinical
Late Preclinical
Phase 1
BR 9001
Oral
Acute Ischemic Stroke (AIS)
*1
BR 4044
Intravenous
Severe Traumatic Brain Injury
*2
BR 9001
Oral
Mild TBI Concussion
BR 4044
Intravenous
Mod-Severe TBI Contusion
BR 4044
Intravenous
Acute AIS Undergoing Thrombectomy
1

BR9001 – Oral, Self-Micro-Emulsifying BR9001 is IND-enabled with a completed 28 day GLP Safety Toxicology PK study in rats completed.

2

BR4044 – Intravenous nano-suspension BR4044 has completed a pivotal efficacy study treating TBI with brain contusion in rats.

Skip to content